[Possibility of using TFX (thymus factor X) in the treatment of systemic lupus erythematosus]
- PMID: 2701749
[Possibility of using TFX (thymus factor X) in the treatment of systemic lupus erythematosus]
Abstract
A case of a 32-year female patient with the systemic lupus erythematosus is presented. The patient was treated with prednisone in a daily dose of 40-60 mg. Due to the exacerbations of the symptoms and advanced renal disorders, the patient was given TFX together with corticotherapy. Thymus factor X is an extract of real thymus of immunorecorrective properties. It specifically acts on the lymphatic system, especially disordered mechanisms of both cellular and humoral immunity. Thymus factor X was given in the dose of 10 mg (one ampoule) i.m. for the three first months followed by one ampoule every three days for the next three months. The patient is given one ampoule of TFX once a week since the 6th months of therapy. Diminishment of the symptoms was observed. The patient is in remission since a one-year follow-up period. It was also possible to reduce the dose of prednisone to 15 mg a day. The patient is controlled every 3 months. Partial normalization of renal functioning and immunological mechanisms are seen. A decrease in antinuclear antibodies and immunoglobulins, normalization in complement components, an increase in T-cells percentage and conversion of the delayed skin reaction are noted. The authors conclude that TFX may be helpful in the treatment of the autoimmunological diseases, including the systemic lupus erythematosus.
Similar articles
-
[Clinical effectiveness of the treatment of systemic lupus erythematosus with preparations of the methylxanthine group and T-activin].Klin Med (Mosk). 1987 Jan;65(1):107-11. Klin Med (Mosk). 1987. PMID: 3550275 Clinical Trial. Russian. No abstract available.
-
High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.Arthritis Rheum. 2003 Jan;48(1):166-73. doi: 10.1002/art.10752. Arthritis Rheum. 2003. PMID: 12528116 Clinical Trial.
-
[Comparison of treatment outcome in patients with rheumatoid arthritis treated with TFX- Polfa or gold salts after a one year follow up].Pol Tyg Lek. 1992 Dec 7-14;47(49-50):1102-4. Pol Tyg Lek. 1992. PMID: 1305735 Polish.
-
[Intravenous administration of immunoglobulins in systemic lupus erythematosus: review of the literature and initial clinical experiences].Infusionsther Transfusionsmed. 1993 Apr;20 Suppl 1:131-5; discussion 136. Infusionsther Transfusionsmed. 1993. PMID: 8499742 Review. German.
-
Sensorineural hearing loss in systemic lupus erythematosus: case report and literature review.J Laryngol Otol. 2008 Dec;122(12):1371-6. doi: 10.1017/S0022215108001783. Epub 2008 Feb 19. J Laryngol Otol. 2008. PMID: 18282337 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical